ADIL
ADIAL PHARMACEUTICALS, INC.Marquee-fund ownership over time
This quarter's activity
New positions opened
None.
Positions exited
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Citadel Advisors 2× in & out | Q4 2025 | Q2 2026 | — | +0% |
| Two Sigma Investments | Q3 2025 | Q4 2025 | — | +0% |
| Renaissance Technologies 2× in & out | Q1 2025 | Q2 2025 | — | +0% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at ADIAL PHARMACEUTICALS, INC.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Apr 9, 2026 — the most recent Form 4 on file — not from today.
- Form 40001213900-26-042054Apr 9, 2026
- Form 40001213900-26-042055Apr 9, 2026
- Form 40001213900-26-042052Apr 9, 2026
- Form 40001213900-26-042053Apr 9, 2026
- Form 40001213900-26-042051Apr 9, 2026
- Form 40001213900-26-042050Apr 9, 2026
- Form 40001213900-25-050021Jun 2, 2025
- Form 40001213900-25-050020Jun 2, 2025
- Form 40001213900-25-050019Jun 2, 2025
- Form 40001213900-25-050018Jun 2, 2025
- Form 40001213900-25-050017Jun 2, 2025
- Form 40001213900-25-050016Jun 2, 2025
- Form 40001213900-25-050015Jun 2, 2025
- Form 40001213900-24-106119Dec 5, 2024
- Form 40001213900-24-099632Nov 18, 2024
Fundamentals
XBRL · ADIAL PHARMACEUTICALS, INC.Annual figures sourced directly from ADIAL PHARMACEUTICALS, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for ADIAL PHARMACEUTICALS, INC. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KCURRENT REPORTMay 11, 2026
- 10-QQUARTERLY REPORTMay 8, 2026
- 8-KCURRENT REPORTApr 9, 2026
- 8-KCURRENT REPORTMar 6, 2026
- 10-KANNUAL REPORTMar 5, 2026
- 8-KCURRENT REPORTMar 3, 2026
- 8-KCURRENT REPORTFeb 24, 2026
- 8-KCURRENT REPORTFeb 4, 2026
- 8-KCURRENT REPORTJan 6, 2026
- DEF 14ADEFINITIVE PROXY STATEMENTJan 6, 2026
- S-3REGISTRATION STATEMENTDec 12, 2025
- 8-KCURRENT REPORTDec 1, 2025
- 8-KCURRENT REPORTNov 14, 2025
- 10-QQUARTERLY REPORTNov 13, 2025
- 8-KCURRENT REPORTSep 16, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Citadel Advisors | Q4 2025 | Q2 2026 | $0.00 | — | +0% |
| Two Sigma Investments | Q3 2025 | Q4 2025 | $0.00 | — | +0% |
| Renaissance Technologies | Q1 2025 | Q2 2025 | $0.00 | — | +0% |
| Citadel Advisors | Q3 2024 | Q2 2025 | $0.00 | — | +0% |
| Renaissance Technologies | Q3 2024 | Q4 2024 | $0.00 | — | +0% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.